<DOC>
	<DOCNO>NCT01606176</DOCNO>
	<brief_summary>To investigate ability cannabis base medicine extract relieve chronic refractory pain neurological origin .</brief_summary>
	<brief_title>A Study Evaluate Effects Cannabis Based Medicine Patients With Pain Neurological Origin</brief_title>
	<detailed_description>Patients Multiple Sclerosis defect neurological function qualify symptom chronic refractory pain , enter seven day baseline period , follow 21 day randomise , double blind , parallel group comparison GW-1000-02 placebo , self-titrated symptom resolution maximum tolerate dose . The ability cannabis base medicine extract relieve chronic refractory pain assess change baseline pain score use Box Scale-11 ( BS-11 ) score recorded patient ' daily diary .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<criteria>Patient , legal representative , willing able give inform consent participation study . Male Female , age 18 year . Diagnosed chronic refractory pain due Multiple Sclerosis defect neurological function . Diagnosed pain , wholly alleviate current analgesic therapy Visit 1 average score 4 Box Scale11 scale four consecutive day lead Visit 2 , : zero = `` pain '' 10 = `` bad possible pain '' . Stable dose pain relieve medication least two week prior study entry . Willing ensure partner use effective contraception study three month thereafter ( applicable female patient child bear potential male patient whose partner child bear potential ) . No cannabinoid use ( cannabis , Marinol Nabilone ) least seven day Visit 1 willing abstain use cannabis study . Able ( investigator 's opinion ) willing comply study requirement . Willing name notify Home Office participation study . Willing allow general practitioner consultant , appropriate , notified participation study . History schizophrenia , psychotic illness , severe personality disorder significant psychiatric disorder depression associate underlying condition . Known history alcohol substance abuse . Severe cardiovascular disorder , ischaemic heart disease , arrhythmia ( well control atrial fibrillation ) , poorly control hypertension severe heart failure . History epilepsy . Female patient pregnant , lactate plan pregnancy course study . Significant renal hepatic impairment . Scheduled elective surgery procedure require general anaesthesia study . Terminally ill inappropriate placebo medication . Any significant disease disorder , opinion investigator , may put patient risk participation study , may influence result study , patient 's ability participate study . Regular levodopa ( Sinemet速 , Sinemet Plus速 , Levodopa , Ldopa , Madopar速 , Benserazide ) therapy within seven day study entry . Known suspected hypersensitivity cannabinoids excipients study medication . Known suspect adverse reaction cannabinoids . Travel outside UK plan study . Donation blood study . Patients participate another research study 12 week lead study entry . Patients previously randomise study . Male patient receive Sildenafil ( Viagra速 ) time study entry unwilling stop medication duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>